DataVXJournal of Biomedical Materials Research Part APaper
journal article·2013-06Open access

Part II: Enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops

Mohd. Abul Kalam, Yasmin Sultana, Asgar Ali, Mohd. Aqil, Anil K. Mishra, Krishna Chuttani, Ibrahim A. Aljuffali, Aws Alshamsan

Journal of Biomedical Materials Research Part A· Volume 101A· Issue 6
Publisher pageOpen full text
Source abstract

Abstract

Abstract This study describes corneal permeation of gatifloxacin from solid lipid nanoparticle (SLN) through the cornea and its effect on corneal hydration level. The aqueous humor levels of gatifloxacin after single topical instillation in Gate® Eyedrops and positively charged SLN‐C were determined. A 3.37‐fold increase in the relative bioavailability was observed with the SLN‐C (AUC0→∞ 2.192 μg mL−1 h) (AUC, area under the curve) as compared to Gate® Eyedrops (AUC0→∞ 0.651 μg mL−1 h). The t1/2 of drug in SLN‐C exhibited a 2.34‐fold higher than Gate® Eyedrops seem to be significantly increased (p > 0.05), Cmax of gatifloxacin from SLN‐C showed 1.09‐fold higher concentration as compared to Gate® Eyedrops. The results suggested that SLNs could enhance ocular bioavailability of gatifloxacin and prolong its residence time in the eyes. Moreover, no signs of ocular irritation were seen with the SLN formulations, indicating their relative safety compared to the marketed drops. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2013.
Source: crossref · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems · Antibiotics Pharmacokinetics and Efficacy

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (30)

Show source-provided references
1. 10.2174/138920105316715810.2174/1389201053167158 ↗
2. 10.1016/j.ijpharm.2008.08.00410.1016/j.ijpharm.2008.08.004 ↗
3. 10.1016/j.ijpharm.2008.07.02810.1016/j.ijpharm.2008.07.028 ↗
4. 10.1016/j.ejpb.2007.07.00610.1016/j.ejpb.2007.07.006 ↗
5. 10.1016/j.ijpharm.2005.05.03610.1016/j.ijpharm.2005.05.036 ↗
6. Chitosan‐sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterization
7. 10.1016/j.addr.2003.12.00210.1016/j.addr.2003.12.002 ↗
8. 10.3109/1061186090333846210.3109/10611860903338462 ↗
9. 10.1080/0193269070168848210.1080/01932690701688482 ↗
10. 10.1016/j.ejpb.2004.03.02810.1016/j.ejpb.2004.03.028 ↗
11. 10.1016/j.ijpharm.2007.12.00710.1016/j.ijpharm.2007.12.007 ↗
12. 10.1080/0363904050030620310.1080/03639040500306203 ↗
13. 10.1016/j.ijpharm.2009.06.02010.1016/j.ijpharm.2009.06.020 ↗
14. 10.1016/j.biomaterials.2006.11.02810.1016/j.biomaterials.2006.11.028 ↗
15. 10.1016/S0168-3659(02)00175-X10.1016/S0168-3659(02)00175-X ↗
16. 10.1016/j.jconrel.2005.11.02010.1016/j.jconrel.2005.11.020 ↗
17. 10.1016/S0378-5173(99)00003-410.1016/S0378-5173(99)00003-4 ↗
18. 10.1016/S0021-9673(02)01536-410.1016/S0021-9673(02)01536-4 ↗
19. 10.1016/j.ijpharm.2007.03.00910.1016/j.ijpharm.2007.03.009 ↗
20. 10.1016/j.jpba.2008.06.00110.1016/j.jpba.2008.06.001 ↗
21. 10.1016/j.ophtha.2006.01.06110.1016/j.ophtha.2006.01.061 ↗
22. 10.1016/j.jcrs.2004.06.04810.1016/j.jcrs.2004.06.048 ↗
23. Schoenwald RD · 1993 · 83
24. 10.1016/j.jpba.2009.12.00810.1016/j.jpba.2009.12.008 ↗
25. 10.1016/j.ijantimicag.2009.08.00210.1016/j.ijantimicag.2009.08.002 ↗
26. Maurice DM · 1970 · 6
27. Bristol Myers Squibb Company. New Drug Application for Tequin (Gatifloxacin Tablets and Injections). Environmental Assessment. Center for Drug Evaluation and Research Website. 2001 Accessed May 31 2006.
28. 10.1111/j.2042-7158.1995.tb06718.x10.1111/j.2042-7158.1995.tb06718.x ↗
29. 10.1016/j.ijpharm.2008.07.01710.1016/j.ijpharm.2008.07.017 ↗
30. 10.1089/jop.2007.012110.1089/jop.2007.0121 ↗